Safety of ceftriaxone in paediatrics: a systematic review protocol. Issue 8 (21st August 2017)

• Record Type: Journal Article
• Authors: Zeng, Linan; Choonara, Imti; Zhang, Lingli; Xue, Song; Chen, Zhe; He, Miaomiao
• Is Part Of: BMJ open. Volume 7:Issue 8(2017)
• Publication Date: 2017-08-21
• Subjects: Ceftriaxone -- Paediatrics -- Safety; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2017-016273
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Ceftriaxone is widely used in children in the treatment of sepsis. However, concerns have been raised about the safety of ceftriaxone, especially in young children. The aim of this review is to systematically evaluate the safety of ceftriaxone in children of all age groups. Methods and analysis: MEDLINE, PubMed, Cochrane Central Register of Controlled Trials, EMBASE, CINAHL, International Pharmaceutical Abstracts and adverse drug reaction (ADR) monitoring systems will be systematically searched for randomised controlled trials (RCTs), cohort studies, case–control studies, cross-sectional studies, case series and case reports evaluating the safety of ceftriaxone in children. The Cochrane risk of bias tool, Newcastle-Ottawa and quality assessment tools developed by the National Institutes of Health will be used for quality assessment. Meta-analysis of the incidence of ADRs from RCTs and prospective studies will be done. Subgroup analyses will be performed for age and dosage regimen. Ethics and dissemination: Formal ethical approval is not required as no primary data are collected. This systematic review will be disseminated through a peer-reviewed publication and at conference meetings. PROSPERO registration number: CRD42017055428.